Combined aqupla, paclitaxel liposome, and docetaxel treatment: survival and biomarker outcomes in recurrent ovarian cancer patients

Abstract

As one lethal malignancy in women's reproductive systems, ovarian cancer (OC) is frequently detected at an advanced phase during diagnosis. when the disease has spread widely. The absence of obvious symptoms and powerful screening tools in the early stages makes treatment difficult and the prognosis poor. Despite the clinical remission that can be achieved in some patients after initial treatment, the recurrence rate is conspicuous, posing a considerable challenge in treating recurrent OC (ROC). In the retrospective analysis, we compared the effects of two treatment regimens, aqupla combined with paclitaxel liposome (NP group) versus aqupla combined with docetaxel (ND group), on survival and biomarkers in patients with ROC. The study included 121 OC patients, and clinical data were collected through an electronic medical record system, outpatient review records, and a follow-up record system. The results revealed a notably higher overall remission rate in the ND group than the NP group, but revealed no notable inter-group discrepancy in toxicities, implying that the aqupla combined with docetaxel regimen may be more effective in platinum-sensitive ROC patients. Additionally, post-treatment CA125 levels were lower in patients in the ND group, suggesting that the regimen may be more effective in reducing tumour load. Survival analysis further revealed that treatment regimen, FIGO stage, number of recurrent lesions, and pretreatment CA125 level were independent prognostic factors affecting patients' 5-year OS and PFS. Overall for ROC patients, especially platinum-sensitive patients, the aqupla in combination with docetaxel regimen provided an improved survival benefit with a comparable safety profile, highlighting the importance of individualised treatment strategies.

Keywords: aqupla; biomarkers; docetaxel; paclitaxel liposome; recurrent ovarian cancer; survival.

Figure 1

Flowchart for the research Paclitaxel liposome treatment (NP group), and Docetaxel treatment (ND group).

Figure 2

Patient Clinical Efficacy Assessment (A) Comparison of the overall number of remissions between drug-resistant and sensitive patients in the NP group. (B) Comparison of the overall number of remissions between drug-resistant patients and sensitive patients in the ND group. (C) Comparison of the overall number of patients in remission between patients in the NP group and patients in the ND group. Paclitaxel liposome treatment (NP group), and Docetaxel treatment (ND group).

Figure 3

Comparison of Tumour Marker Changes Before and After Treatment in Patients (A) Inter-group Comparison of CEA Levels Before and After Treatment (B) Inter-group Comparison of CA125 Levels Before and After Treatment (C) Inter-group Comparison of CA19–9 Levels Before and After Treatment Note: Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA125), Cancer Antigen 19–9 (CA19–9), Paclitaxel liposome treatment (NP group), and Docetaxel treatment (ND group).

Figure 4

Comparison of changes in immune function indexes before and after treatment of patients (A) Inter-group comparison of CD3 level changes before and after treatment (B) Inter-group comparison of CD4 level changes before and after treatment. (C) Inter-group comparison of CD8 level changes before and after treatment. Cluster of Differentiation 3 (CD3), Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Paclitaxel liposome treatment (NP group), and Docetaxel treatment (ND group).

Figure 5

Survival curves for 5-year OS prognostic factors (A) 5-year OS curves comparing patients with different FIGO staging (B) 5-year OS curves comparing patients with different number of recurrent lesions (C) 5-year OS curves comparing patients with high and low CA125 expression. Overall survival rate (OS), International Federation of Gynecology and Obstetrics Staging(FIGO), and Cancer Antigen 125 (CA125).

Figure 6

Survival curves on prognostic factors for PFS (A) PFS curves for comparing various treatment regimens in patients. (B) PFS curves based on different FIGO staging in patients. (C) PFS curves of patients with varying numbers of recurrent lesions. (D) PFS curves comparing patients with high and low CA125 expression Note: Progression-Free Survival (PFS), International Federation of Gynecology and Obstetrics Staging(FIGO), and Cancer Antigen 125 (CA125).